The roles of K + channels in cancer

Nature Reviews Cancer

Volumn 14, Issue 1, 2014, Pages 39-48

  Pardo, Luis A ^a   Stühmer, Walter ^a  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL;

ANGIOGENESIS; APOPTOSIS; CANCER PATIENT; CANCER PROGNOSIS; CELL ADHESION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SPECIFICITY; CELL TYPE; CELL VOLUME; DRUG TARGETING; ELECTROCHEMICAL ANALYSIS; GENE EXPRESSION; HUMAN; MIGRATION; NEOPLASM; NERVE CELL EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 84890992887     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3635     Document Type: Review

References (156)

1. Wulff, H., Castle, N. A. & Pardo, L. A. Voltage-gated potassium channels as therapeutic targets. Nature Rev. Drug Discov. 8, 982-1001 (2009).
2. Downie, B. R. et al. Eag1 expression interferes with hypoxia homeostasis and induces angiogenesis in tumors. J. Biol. Chem. 283, 36234-36240 (2008).
3. Hegle, A. P., Marble, D. D. & Wilson, G. F. A voltage-driven switch for ion-independent signaling by ether-À-gogo K+ channels. Proc. Natl Acad. Sci. USA 103, 2886-2891 (2006).
4. Gutman, G. A. et al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol. Rev. 57, 473-508 (2005).
5. Kaczmarek, L. K. Non-conducting functions of voltage-gated ion channels. Nature Rev. Neurosci. 7, 761-771 (2006).
6. Huber, S. M. Oncochannels. Cell Calcium 53, 241-255 (2013).
7. Choi, M. et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331, 768-772 (2011).
8. Hofmann, G. et al. HERG K+ channels activation during β1 integrin-mediated adhesion to fibronectin induces an upregulation of αvβ3 integrin in the preosteoclastic leukemia cell line FLG 29.1. J. Biol. Chem. 276, 4923-4931 (2001).
9. Munoz, C. et al. Stimulation of HERG channel activity by β-catenin. PLoS ONE 7, e43353 (2012).
10. Wu, X. et al. p38 MAPK regulates the expression of ether a gogo potassium channel in human osteosarcoma cells. Radiol Oncol. 47, 42-49 (2013).
11. Alvarez-Baron, C. P., Jonsson, P., Thomas, C., Dryer, S. E. & Williams, C. The two-pore domain potassium channel KCNK5: induction by estrogen receptor α and role in proliferation of breast cancer cells. Mol. Endocrinol. 25, 1326-1336 (2011).
12. Cho, Y. G. et al. Genetic and expression analysis of the KCNRG gene in hepatocellular carcinomas. Exp. Mol. Med. 38, 247-255 (2006).
13. Ivanov, D. V. et al. A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3. FEBS Lett. 539, 156-160 (2003).
14. Usman, H. & Mathew, M. K. Potassium channel regulator KCNRG regulates surface expression of Shaker-type potassium channels. Biochem. Biophys. Res. Commun. 391, 1301-1305 (2010).
15. Brevet, M. et al. Deregulation of 2 potassium channels in pancreas adenocarcinomas: implication of KV1.3 gene promoter methylation. Pancreas 38, 649-654 (2009).
16. Brevet, M., Haren, N., Sevestre, H., Merviel, P. & Ouadid-Ahidouch, H. DNA methylation of KV1.3 potassium channel gene promoter is associated with poorly differentiated breast adenocarcinoma. Cell Physiol. Biochem. 24, 25-32 (2009).
17. Feng, Q. et al. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol. Biomarkers Prev. 17, 645-654 (2008).
18. Cicek, M. S. et al. Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel. Hum. Mol. Genet. 22, 3038-3047 (2013).
19. Menendez, S. T. et al. Frequent aberrant expression of the human ether à gogo (hEAG1) potassium channel in head and neck cancer: pathobiological mechanisms and clinical implications. J. Mol. Med. 90, 1173-1184 (2012).
20. Bianchi, L. et al. herg encodes a K+ current highly conserved in tumors of different histogenesis: A selective advantage for cancer cells? Cancer Res. 58, 815-822 (1998).
21. Cheong, A. et al. Downregulated REST transcription factor is a switch enabling critical potassium channel expression and cell proliferation. Mol. Cell 20, 45-52 (2005).
22. Lin, H. et al. Transcriptional and post-transcriptional mechanisms for oncogenic overexpression of ether à gogo K+ channel. PLoS ONE 6, e20362 (2011).
23. Diaz, L. et al. Estrogens and human papilloma virus oncogenes regulate human etheragogo1 potassium channel expression. Cancer Res. 69, 3300-3307 (2009).
24. Liu, R. G., Wang, W. J., Song, N., Chen, Y. Q. & Li, L. H. Diazoxide preconditioning alleviates apoptosis of hippocampal neurons induced by anoxia-reoxygenation in vitro through upregulation of Bcl2/ Bax protein ratio. Sheng Li Xue Bao 58, 345-350 (2006).
25. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P. M. The E6 oncoprotein encoded by human papillomavirus type16 and type18 promotes the degradation of p53. Cell 63, 1129-1136 (1990).
26. Hwang, S. G., Lee, D. Y., Kim, J. Y., Seo, T. G. & Choe, J. H. Human papillomavirus type 16 E7 binds to E2F1 and activates E2F1driven transcription in a retinoblastoma protein-independent manner. J. Biol. Chem. 277, 2923-2930 (2002).
27. Borowiec, A. S. et al. IGF1 activates hEAG K+ channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation. J. Cell. Physiol. 212, 690-701 (2007).
28. Sabbatini, P. & McCormick, F. Phosphoinositide 3OH kinase (PI3K) and PKB/Akt delay the onset of p53mediated, transcriptionally dependent apoptosis. J. Biol. Chem. 274, 24263-24269 (1999).
29. Bai, Y. et al. MiR2963p regulates cell growth and multi-drug resistance of human glioblastoma by targeting etheragogo (EAG1). Eur. J. Cancer 49, 710-724 (2013).
30. Yoon, A.R. et al. MicroRNA296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3Ŷ untranslated region. Nucleic Acids Res. 39, 8078-8091 (2011).
31. Ousingsawat, J. et al. Expression of voltage-gated potassium channels in human and mouse colonic carcinoma. Clin. Cancer Res. 13, 824-831 (2007).
32. Pardo, L. A. et al. Oncogenic potential of EAG K+ channels. EMBO J. 18, 5540-5547 (1999).
33. Ufartes, R. et al. Behavioural and functional characterization of Kv10.1 (Eag1) knockout mice. Hum. Mol. Genet. 22, 2247-2262 (2013).
34. Martin, S. et al. Eag1 potassium channel immunohistochemistry in the CNS of adult rat and selected regions of human brain. Neuroscience 155, 833-844 (2008).
35. Hemmerlein, B. et al. Overexpression of Eag1 potassium channels in clinical tumours. Mol. Cancer 5, 41 (2006).
36. de Queiroz, F. M., Suarez-Kurtz, G., Stühmer, W. & Pardo, L. A. Ether a gogo potassium channel expression in soft tissue sarcoma patients. Mol. Cancer 5, 42 (2006).
37. Agarwal, J. R., Griesinger, F., Stühmer, W. & Pardo, L. A. The potassium channel Ether à gogo is a novel prognostic factor with functional relevance in acute myeloid leukemia. Mol. Cancer 9, 18 (2010).
38. Asher, V. et al. The Eag potassium channel as a new prognostic marker in ovarian cancer. Diagn. Pathol. 5, 78 (2010).
39. Ding, X. W., Luo, H. S., Jin, X., Yan, J. J. & Ai, Y. W. Aberrant expression of Eag1 potassium channels in gastric cancer patients and cell lines. Med. Oncol. 24, 345-350 (2007).
40. Ding, X. W., Yan, J. J., An, P., Lu, P. & Luo, H. S. Aberrant expression of ether a gogo potassium channel in colorectal cancer patients and cell lines. World J. Gastroenterol. 13, 1257-1261 (2007).
41. Wadhwa, S., Wadhwa, P., Dinda, A. K. & Gupta, N. P. Differential expression of potassium ion channels in human renal cell carcinoma. Int. Urol. Nephrol. 41, 251-257 (2009).
42. Gómez-Varela, D. et al. Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res. 67, 7343-7349 (2007).
43. Hartung, F., Stühmer, W. & Pardo, L. A. Tumor cell-selective apoptosis induction through targeting of KV10.1 via bifunctional TRAIL antibody. Mol. Cancer 10, 109 (2011).
44. Becchetti, A. & Arcangeli, A. Integrins and ion channels in cell migration: implications for neuronal development, wound healing and metastatic spread. Adv. Exp. Med. Biol. 674, 107-123 (2010).
45. Schwab, A., Fabian, A., Hanley, P. J. & Stock, C. Role of ion channels and transporters in cell migration. Physiol. Rev. 92, 1865-1913 (2012).
46. Rezzonico, R. et al. Focal adhesion kinase pp125FAK interacts with the large conductance calcium-activated hSlo potassium channel in human osteoblasts: potential role in mechanotransduction. J. Bone Miner. Res. 18, 1863-1871 (2003).
47. Wei, J. F. et al. Formation of Kv2.1FAK complex as a mechanism of FAK activation, cell polarization and enhanced motility. J. Cell. Physiol. 217, 544-557 (2008).
48. Cheng, L., Yung, A., Covarrubias, M. & Radice, G. L. Cortactin is required for Ncadherin regulation of Kv1.5 channel function. J. Biol. Chem. 286, 20478-20489 (2011).
49. Hattan, D., Nesti, E., Cachero, T. G. & Morielli, A. D. Tyrosine phosphorylation of Kv1.2 modulates its interaction with the actin-binding protein cortactin. J. Biol. Chem. 277, 38596-38606 (2002).
50. Bittner, S. et al. The TASK1 channel inhibitor A293 shows efficacy in a mouse model of multiple sclerosis. Exp. Neurol. 238, 149-155 (2012).
51. Tian, L. et al. A noncanonical SH3 domain binding motif links BK channels to the actin cytoskeleton via the SH3 adapter cortactin. FASEB J. 20, 2588-2590 (2006).
52. Williams, M. R., Markey, J. C., Doczi, M. A. & Morielli, A. D. An essential role for cortactin in the modulation of the potassium channel Kv1.2. Proc. Natl Acad. Sci. USA 104, 17412-17417 (2007).
53. Levite, M. et al. Extracellular K+ and opening of voltage-gated potassium channels activate T cell integrin function: Physical and functional association between Kv1.3 channels and β1 integrins. J. Exp. Med. 191, 1167-1176 (2000).
54. Cherubini, A. et al. Human etheragogorelated gene 1 channels are physically linked to β1 integrins and modulate adhesion-dependent signaling. Mol. Biol. Cell 16, 2972-2983 (2005).
55. Pillozzi, S. et al. VEGFR1 (FLT1), β1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood 110, 1238-1250 (2007).
56. Pillozzi, S. & Arcangeli, A. Physical and functional interaction between integrins and hERG1 channels in cancer cells. Adv. Exp. Med. Biol. 674, 55-67 (2010).
57. Li, H. et al. The role of hERG1 K+ channels and a functional link between hERG1 K+ channels and SDF1 in acute leukemic cell migration. Exp. Cell Res. 315, 2256-2264 (2009).
58. Afrasiabi, E. et al. Expression and significance of HERG (KCNH2) potassium channels in the regulation of MDAMB435S melanoma cell proliferation and migration. Cell Signal 22, 57-64 (2010).
59. Asghar, M. Y., Viitanen, T., Kemppainen, K. & Tornquist, K. Sphingosine 1phosphate and human ether-À-gogorelated gene potassium channels modulate migration in human anaplastic thyroid cancer cells. Endocr. Relat. Cancer 19, 667-680 (2012).
60. Arcangeli, A. et al. A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells. J. Physiol. 489, 455-471 (1995).
61. Arcangeli, A. et al. HERG- and IRK-like inward rectifier currents are sequentially expressed during neuronal development of neural crest cells and their derivatives. Eur. J. Neurosci. 9, 2596-2604 (1997).
62. Pillozzi, S. et al. HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia 16, 1791-1798 (2002).
63. Smith, G. A. M. et al. Functional upregulation of HERG K+ channels in neoplastic hematopoietic cells. J. Biol. Chem. 277, 18528-18534 (2002).
64. Lastraioli, E. et al. herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res. 64, 606-611 (2004).
65. Shao, X. D. et al. Expression and significance of HERG protein in gastric cancer. Cancer Biol. Ther. 7, 45-50 (2008).
66. Ding, X. W. et al. Prognostic significance of hERG1 expression in gastric cancer. Dig. Dis. Sci. 55, 1004-1010 (2010).
67. Dolderer, J. H. et al. HERG1 gene expression as a specific tumor marker in colorectal tissues. Ejso 36, 72-77 (2010).
68. Glassmeier, G. et al. Inhibition of HERG1 K+ channel protein expression decreases cell proliferation of human small cell lung cancer cells. Pflugers Arch. 463, 365-376 (2012).
69. Menendez, S. T. et al. Role of HERG1 potassium channel in both malignant transformation and disease progression in head and neck carcinomas. Mod. Pathol. 25, 1069-1078 (2012).
70. Lastraioli, E. et al. hERG1 channels in human esophagus: evidence for their aberrant expression in the malignant progression of Barrett's esophagus. J. Cell. Physiol. 209, 398-404 (2006).
71. Masi, A. et al. hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br. J. Cancer 93, 781-792 (2005).
72. Crociani, O. et al. Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells. J. Biol. Chem. 278, 2947-2955 (2003).
73. Shao, X. D. et al. The potent inhibitory effects of cisapride, a specific blocker for human etheragogorelated gene (HERG) channel, on gastric cancer cells. Cancer Biol. Ther. 4, 295-301 (2005).
74. Zhao, J., Wei, X. L., Jia, Y. S. & Zheng, J. Q. Silencing of herg gene by shRNA inhibits SHSY5Y cell growth in vitro and in vivo. Eur. J. Pharmacol. 579, 50-57 (2008).
75. Vandenberg, J. I. et al. hERG K+ channels: structure, function, and clinical significance. Physiol. Rev. 92, 1393-1478 (2012).
76. Guasti, L. et al. Identification of a posttranslational mechanism for the regulation of hERG1 K+ channel expression and hERG1 current density in tumor cells. Mol. Cell. Biol. 28, 5043-5060 (2008).
77. Schwab, A., Hanley, P., Fabian, A. & Stock, C. Potassium channels keep mobile cells on the go. Physiol. (Bethesda) 23, 212-220 (2008).
78. Schwab, A., Wojnowski, L., Gabriel, K. & Oberleithner, H. Oscillating activity of a Ca2+-sensitive K+ channel. A prerequisite for migration of transformed Madin-Darby canine kidney focus cells. J. Clin. Invest. 93, 1631-1636 (1994).
79. Reinhardt, J., Golenhofen, N., Pongs, O., Oberleithner, H. & Schwab, A. Migrating transformed mdck cells are able to structurally polarize a voltage-activated K+ channel. Proc. Natl Acad. Sci. USA 95, 5378-5382 (1998).
80. Schwab, A., Reinhardt, J., Schneider, S. W., Gassner, B. & Schuricht, B. K+ channel-dependent migration of fibroblasts and human melanoma cells. Cell Physiol. Biochem. 9, 126-132 (1999).
81. Schwab, A., Schuricht, B., Seeger, P., Reinhardt, J. & Dartsch, P. C. Migration of transformed renal epithelial cells is regulated by K+ channel modulation of actin cytoskeleton and cell volume. Pflugers Arch. 438, 330-337 (1999).
82. Liu, D., Lu, C., Wan, R., Auyeung, W. W. & Mattson, M. P. Activation of mitochondrial ATP-dependent potassium channels protects neurons against ischemia-induced death by a mechanism involving suppression of Bax translocation and cytochrome c release. J. Cereb. Blood Flow Metab. 22, 431-443 (2002).
83. Ransom, C. B., Liu, X. & Sontheimer, H. BK channels in human glioma cells have enhanced calcium sensitivity. Glia 38, 281-291 (2002).
84. Weaver, A. K., Liu, X. & Sontheimer, H. Role for calcium-activated potassium channels (BK) in growth control of human malignant glioma cells. J. Neurosci. Res. 78, 224-234 (2004).
85. Sciaccaluga, M. et al. CXCL12induced glioblastoma cell migration requires intermediate conductance Ca2+-activated K+ channel activity. Am. J. Physiol. Cell Physiol. 299, C175-C184 (2010).
86. Catacuzzeno, L., Fioretti, B. & Franciolini, F. Expression and role of the intermediate-conductance calcium-activated potassium channel KCa3.1 in glioblastoma. J. Signal Trans. 2012, 421564 (2012).
87. Ruggieri, P. et al. The inhibition of KCa3.1 channels activity reduces cell motility in glioblastoma derived cancer stem cells. PLoS ONE 7, e47825 (2012).
88. Steinle, M. et al. Ionizing radiation induces migration of glioblastoma cells by activating BK K+ channels. Radiother. Oncol. 101, 122-126 (2011).
89. Potier, M. et al. Altered SK3/KCa2.3mediated migration in adenomatous polyposis coli (Apc) mutated mouse colon epithelial cells. Biochem. Biophys. Res. Commun. 397, 42-47 (2010).
90. Chantome, A. et al. KCa2.3 channel-dependent hyperpolarization increases melanoma cell motility. Exp. Cell Res. 315, 3620-3630 (2009).
91. Potier, M. et al. Identification of SK3 channel as a new mediator of breast cancer cell migration. Mol. Cancer Ther. 5, 2946-2953 (2006).
92. Girault, A. et al. New alkyl-lipid blockers of SK3 channels reduce cancer cell migration and occurrence of metastasis. Curr. Cancer Drug Targets 11, 1111-1125 (2011).
93. Hammadi, M. et al. Human ether agogo K+ channel 1 (hEag1) regulates MDAMB231 breast cancer cell migration through Orai1dependent calcium entry. J. Cell. Physiol. 227, 3837-3846 (2012).
94. Chantome, A. et al. Pivotal role of the lipid raft SK3Orai1 complex in human cancer cell migration and bone metastases. Cancer Res. 73, 4852-4861 (2013).
95. Hoffmann, E. K. & Pedersen, S. F. Cell volume homeostatic mechanisms: effectors and signalling pathways. Acta Physiol. (Oxf.) 202, 465-485 (2011).
96. Hoffmann, E. K. Ion channels involved in cell volume regulation: effects on migration, proliferation, and programmed cell death in non adherent EAT cells and adherent ELA cells. Cell Physiol. Biochem. 28, 1061-1078 (2011).
97. Völkl, H., Paulmichl, M. & Lang, F. Cell volume regulation in renal cortical cells. Ren Physiol. Biochem. 11, 158-173 (1988).
98. Rouzaire-Dubois, B., Gerard, V. & Dubois, J. M. Involvement of K+ channels in the quercetin-induced inhibition of neuroblastoma cell growth. Pflugers Arch. 423, 202-205 (1993).
99. Dubois, J.M. & Rouzaire-Dubois, B. The influence of cell volume changes on tumour cell proliferation. Eur. Biophys. J. 33, 227-232 (2004).
100. Huang, X. et al. Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes Dev. 26, 1780-1796 (2012).
101. Neylon, C. B., Avdonin, P. V., Larsen, M. A. & Bobik, A. Rat aortic smooth muscle cells expressing charybdotoxin-sensitive potassium channels exhibit enhanced proliferative responses. Clin. Exp. Pharmacol. Physiol. 21, 117-120 (1994).
102. Wiecha, J. et al. Blockade of Ca2+-activated K+ channels inhibits proliferation of human endothelial cells induced by basic fibroblast growth factor. J. Vasc. Res. 35, 363-371 (1998).
103. Faehling, M., Koch, E. D., Raithel, J., Trischler, G. & Waltenberger, J. Vascular endothelial growth factora activates Ca2+-activated K+ channels in human endothelial cells in culture. Int. J. Biochem. Cell Biol. 33, 337-346 (2001).
104. Neylon, C. B. Potassium channels and vascular proliferation. Vasc. Pharmacol. 38, 35-41 (2002).
105. Miguel-Velado, E. et al. Cell cycle-dependent expression of Kv3.4 channels modulates proliferation of human uterine artery smooth muscle cells. Cardiovasc. Res. 86, 383-391 (2010).
106. Cheong, A. et al. Potent suppression of vascular smooth muscle cell migration and human neointimal hyperplasia by KV1.3 channel blockers. Cardiovasc. Res. 89, 282-289 (2011).
107. Cidad, P. et al. Kv1.3 channels can modulate cell proliferation during phenotypic switch by an ion-flux independent mechanism. Arterioscler. Thromb. Vasc. Biol. 32, 1299-1307 (2012).
108. Bi, D. et al. The intermediate-conductance calcium-activated potassium channel KCa3.1 regulates vascular smooth muscle cell proliferation via controlling calcium-dependent signaling. J Biol Chem, 15843-15853 (2013).
109. Zhao, L. M., Su, X. L., Wang, Y., Li, G. R. & Deng, X. L. KCa3.1 channels mediate the increase of cell migration and proliferation by advanced glycation endproducts in cultured rat vascular smooth muscle cells. Lab. Invest. 93, 159-167 (2013).
110. Ouadid-Ahidouch, H. et al. Changes in the K+ current-density of MCF7 cells during progression through the cell cycle: Possible involvement of a hether.agogo K+ channel. Recept. Channels 7, 345-356 (2001).
111. Benito, J. et al. Pronounced hypoxia in models of murine and human leukemia: High efficacy of hypoxia-activated prodrug PR104. PLoS ONE 6, e23108 (2011).
112. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
113. Urrego-Blanco, D., Tomczak, A. P., Zahed, F., Stühmer, W. & Pardo, L. A. Potassium channels in cell cycle and cell proliferation. Philos Trans B (in the press).
114. DeCoursey, T. E., Chandy, K. G., Gupta, S. & Cahalan, M. D. Voltage-gated K+ channels in human T lymphocytes: A role in mitogenesis? Nature 307, 465-468 (1984).
115. Blackiston, D. J., McLaughlin, K. A. & Levin, M. Bioelectric controls of cell proliferation: ion channels, membrane voltage and the cell cycle. Cell Cycle 8, 3519-3528 (2009).
116. Cahalan, M. D. & Chandy, K. G. The functional network of ion channels in T lymphocytes. Immunol. Rev. 231, 59-87 (2009).
117. Faouzi, M., Chopin, V., Ahidouch, A. & Ouadid- Ahidouch, H. Intermediate Ca2+-sensitive K+ channels are necessary for prolactin-induced proliferation in breast cancer cells. J. Membr. Biol. 234, 47-56 (2010).
118. Lallet-Daher, H. et al. Intermediate-conductance Ca2+- activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry. Oncogene 28, 1792-1806 (2009).
119. Prevarskaya, N., Skryma, R. & Shuba, Y. Ion channels and the hallmarks of cancer. Trends Mol. Med. 16, 107-121 (2010).
120. Skelding, K. A., Rostas, J. A. P. & Verrills, N. M. Controlling the cell cycle: The role of calcium/ calmodulin-stimulated protein kinases I and II. Cell Cycle 10, 631-639 (2011).
121. Kahl, C. R. & Means, A. R. Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. Endocr. Rev. 24, 719-736 (2003).
122. Patel, A. J. & Lazdunski, M. The 2Pdomain K+ channels: role in apoptosis and tumorigenesis. Pflugers Arch. 448, 261-273 (2004).
123. McFerrin, M. B., Turner, K. L., Cuddapah, V. A. & Sontheimer, H. Differential role of IK and BK potassium channels as mediators of intrinsic and extrinsic apoptotic cell death. Am. J. Physiol. Cell Physiol. 303, C1070-C1078 (2012).
124. Borjesson, S. I., Englund, U. H., Asif, M. H., Willander, M. & Elinder, F. Intracellular K+ concentration decrease is not obligatory for apoptosis. J. Biol. Chem. 286, 39823-39828 (2011).
125. Benitez-Rangel, E., Garcia, L., Namorado, M. C., Reyes, J. L. & Guerrero-Hernandez, A. Ion channel inhibitors block caspase activation by mechanisms other than restoring intracellular potassium concentration. Cell Death Dis. 2, e113 (2011).
126. Nagata, K. et al. Nicorandil inhibits oxidative stress-induced apoptosis in cardiac myocytes through activation of mitochondrial ATP-sensitive potassium channels and a nitrate-like effect. J. Mol. Cell Cardiol 35, 1505-1512 (2003).
127. Qian, X. et al. Glibenclamide exerts an antitumor activity through reactive oxygen species-cjun NH2- terminal kinase pathway in human gastric cancer cell line MGC803. Biochem. Pharmacol. 76, 1705-1715 (2008).
128. Wang, L. et al. The protective roles of mitochondrial ATP-sensitive potassium channels during hypoxia- ischemia-reperfusion in brain. Neurosci. Lett. 491, 63-67 (2011).
129. Foster, D. B. et al. Mitochondrial ROMK channel is a molecular component of mitoKATP. Circ. Res. 111, 446-454 (2012).
130. Kim, Y., Bang, H. & Kim, D. TASK3, a new member of the tandem pore K+ channel family. J. Biol. Chem. 275, 9340-9347 (2000).
131. Mu, D. et al. Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell 3, 297-302 (2003).
132. Lee, G. W. et al. Reduction of breast cancer cell migration via upregulation of TASK3 two-pore domain K+ channel. Acta Physiol. (Oxf.) 204, 513-524 (2012).
133. Pei, L. et al. Oncogenic potential of TASK3 (Kcnk9) depends on K+ channel function. Proc. Natl Acad. Sci. USA 100, 7803-7807 (2003).
134. Lauritzen, I. et al. K+-dependent cerebellar granule neuron apoptosis. Role of TASK leak K+ channels. J. Biol. Chem. 278, 32068-32076 (2003).
135. Meuth, S. G. et al. The two-pore domain potassium channel TASK3 functionally impacts glioma cell death. J. Neurooncol 87, 263-270 (2008).
136. Rusznak, Z. et al. Mitochondrial expression of the two-pore domain TASK3 channels in malignantly transformed and non-malignant human cells. Virchows Arch. 452, 415-426 (2008).
137. Innamaa, A. et al. Expression and prognostic significance of the oncogenic K2P potassium channel KCNK9 (TASK3) in ovarian carcinoma. Anticancer Res. 33, 1401-1408 (2013).
138. Bock, J., Szabo, I., Jekle, A. & Gulbins, E. Actinomycin Dinduced apoptosis involves the potassium channel Kv1.3. Biochem. Biophys. Res. Commun. 295, 526-531 (2002).
139. Szabo, I. et al. Mitochondrial potassium channel Kv1.3 mediates Bax-induced apoptosis in lymphocytes. Proc. Natl Acad. Sci. USA 105, 14861-14866 (2008).
140. Gulbins, E., Sassi, N., Grassme, H., Zoratti, M. & Szabo, I. Role of Kv1.3 mitochondrial potassium channel in apoptotic signalling in lymphocytes. Biochim. Biophys. Acta 1797, 1251-1259 (2010).
141. Leanza, L. et al. Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells. EMBO Mol. Med. 4, 577-593 (2012).
142. Leanza, L., Zoratti, M., Gulbins, E. & Szabo, I. Induction of apoptosis in macrophages via Kv1.3 and Kv1.5 potassium channels. Curr. Med. Chem. 19, 5394-5404 (2012).
143. Sassi, N. et al. An investigation of the occurrence and properties of the mitochondrial intermediate-conductance Ca2+-activated K+ channel mtKCa3.1. Biochim. Biophys. Acta 1797, 1260-1267 (2010).
144. Pillozzi, S. et al. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood 117, 902-914 (2011).
145. Suzuki, Y. et al. Depolarization potentiates TRAIL-induced apoptosis in human melanoma cells: role for ATP-sensitive K+ channels and endoplasmic reticulum stress. Int. J. Oncol. 41, 465-475 (2012).
146. Gong, J. H., Liu, X. J., Shang, B. Y., Chen, S. Z. & Zhen, Y. S. HERG K+ channel related chemosensitivity to sparfloxacin in colon cancer cells. Oncol. Rep. 23, 1747-1756 (2010).
147. Ganapathi, S. B., Kester, M. & Elmslie, K. S. State-dependent block of HERG potassium channels by Rroscovitine: implications for cancer therapy. Am. J. Physiol. Cell Physiol. 296, C701-C710 (2009).
148. Ortiz, C. S. et al. Eag1 potassium channels as markers of cervical dysplasia. Oncol. Rep. 26, 1377-1383 (2011).
149. Chen, S. Z., Jiang, M. & Zhen, Y. S. HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin. Cancer Chemother. Pharmacol. 56, 212-220 (2005).
150. Zhang, R. et al. Human etheragogorelated gene expression is essential for cisplatin to induce apoptosis in human gastric cancer. Oncol. Rep. 27, 433-440 (2012).
151. Asher, V., Sowter, H., Shaw, R., Bali, A. & Khan, R. Eag and HERG potassium channels as novel therapeutic targets in cancer. World J. Surg. Oncol. 8, 113 (2010).
152. Sontheimer, H. An unexpected role for ion channels in brain tumor metastasis. Exp. Biol. Med. (Maywood) 233, 779-791 (2008).
153. Jahchan, N. S. et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discovery http://dx.doi. org/10.1158/21598290.CD130183 (2013).
154. Ninkovic, M., Mitkovski, M., Kohl, T., Stmer, W. & Pardo, L. A. Physical and functional interaction of KV10.1 with Rabaptin5 impacts ion channel trafficking. FEBS Lett. 586, 3077-3084 (2012).
155. Herrmann, S., Ninkovic, M., Kohl, T., Linczi, E. & Pardo, L. A. Cortactin controls surface expression of the voltage-gated potassium channel KV10.1. J. Biol. Chem. 287, 44151-44163 (2012).
156. Farias, L. M. B. et al. Ether gogo potassium channels as human cervical cancer markers. Cancer Res. 64, 6996-7001 (2004).